KR20160135372A - 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물 - Google Patents

리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물 Download PDF

Info

Publication number
KR20160135372A
KR20160135372A KR1020167032103A KR20167032103A KR20160135372A KR 20160135372 A KR20160135372 A KR 20160135372A KR 1020167032103 A KR1020167032103 A KR 1020167032103A KR 20167032103 A KR20167032103 A KR 20167032103A KR 20160135372 A KR20160135372 A KR 20160135372A
Authority
KR
South Korea
Prior art keywords
polyethylene glycol
pharmaceutical composition
active agent
peg
aqueous solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020167032103A
Other languages
English (en)
Korean (ko)
Inventor
바그와티 피. 카브라
말레이 고쉬
Original Assignee
알콘 리서치, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알콘 리서치, 리미티드 filed Critical 알콘 리서치, 리미티드
Publication of KR20160135372A publication Critical patent/KR20160135372A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020167032103A 2009-03-03 2010-03-03 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물 Abandoned KR20160135372A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15692209P 2009-03-03 2009-03-03
US61/156,922 2009-03-03
PCT/US2010/026033 WO2010101992A1 (en) 2009-03-03 2010-03-03 Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020117023001A Division KR20110130454A (ko) 2009-03-03 2010-03-03 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물

Publications (1)

Publication Number Publication Date
KR20160135372A true KR20160135372A (ko) 2016-11-25

Family

ID=42678800

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167032103A Abandoned KR20160135372A (ko) 2009-03-03 2010-03-03 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물
KR1020117023001A Ceased KR20110130454A (ko) 2009-03-03 2010-03-03 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020117023001A Ceased KR20110130454A (ko) 2009-03-03 2010-03-03 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물

Country Status (12)

Country Link
US (2) US20100227905A1 (cg-RX-API-DMAC7.html)
EP (1) EP2403335B1 (cg-RX-API-DMAC7.html)
JP (1) JP5583146B2 (cg-RX-API-DMAC7.html)
KR (2) KR20160135372A (cg-RX-API-DMAC7.html)
CN (1) CN102340991B (cg-RX-API-DMAC7.html)
AU (1) AU2010221369B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1012302A2 (cg-RX-API-DMAC7.html)
CA (1) CA2753690A1 (cg-RX-API-DMAC7.html)
ES (1) ES2508290T3 (cg-RX-API-DMAC7.html)
MX (1) MX2011008731A (cg-RX-API-DMAC7.html)
WO (1) WO2010101992A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201105505B (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973142B2 (en) 2006-04-07 2011-07-05 Warner Chilcott Company Antibodies that bind human protein tyrosine phosphatase beta (HPTPβ)
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
MX2011007420A (es) 2009-07-06 2011-12-14 Akebia Therapeutics Inc Compuestos, composiciones y metodos para prevenir la metastasis de las celulas cancerigenas.
CA2791278C (en) 2010-02-25 2015-11-24 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
AU2011282252B2 (en) * 2010-07-21 2014-08-21 Alcon Research, Ltd. Pharmaceutical composition with enhanced solubility characteristics
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
US20140160236A1 (en) * 2011-07-29 2014-06-12 The Regents Of The University Of California Lensfree holographic microscopy using wetting films
EP3505182A1 (en) 2011-10-13 2019-07-03 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
CA2863632C (en) 2012-01-19 2017-07-11 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
EP2825206A1 (en) 2012-03-16 2015-01-21 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
US10159743B2 (en) 2012-03-16 2018-12-25 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
HK1208162A1 (en) 2012-05-03 2016-02-26 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
EP3808339B1 (en) 2012-05-03 2025-11-12 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9889208B2 (en) 2012-05-04 2018-02-13 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
MX368142B (es) * 2013-04-30 2019-09-20 Intas Pharmaceuticals Ltd Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.
WO2015127389A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic enema formulations and methods of use
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
RU2729731C2 (ru) 2014-12-15 2020-08-11 Зе Джонс Хопкинс Юниверсити Составы на основе сунитиниба и способы их применения для лечения глазных заболеваний
KR20240126072A (ko) 2015-01-27 2024-08-20 더 존스 홉킨스 유니버시티 점막표면에서 활성제의 향상된 수송을 위한 저장성 하이드로겔 제제
EP4414032A3 (en) 2015-09-23 2024-11-06 EyePoint Pharmaceuticals, Inc. Methods of treating intraocular pressure with activators of tie-2
EP3373978A4 (en) 2015-11-12 2019-06-26 Graybug Vision, Inc. AGGREGATION OF MICROPARTICLES FOR THERAPY
CA3056923A1 (en) 2017-03-23 2018-09-27 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
WO2018209155A1 (en) 2017-05-10 2018-11-15 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
WO2020210805A1 (en) 2019-04-11 2020-10-15 The Johns Hopkins University Nanoparticles for drug delivery to brain
AU2020264969B2 (en) 2019-04-29 2025-06-05 EyePoint, Inc. Tie-2 activators targeting the schlemm's canal
EP4065131B1 (en) * 2019-11-28 2024-09-18 Caprika Srl Rectal-use composition for the treatment of constipation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
HU220864B1 (en) * 1993-04-16 2002-06-29 Wakamoto Pharma Co Ltd Reversible, thermally gelling water-base medicinal compositions
CN1126545C (zh) * 1996-05-07 2003-11-05 东丽株式会社 眼科用制剂
SI1638941T1 (sl) * 2003-05-22 2010-11-30 Abbott Lab Inhibitorji indazol benzizoksazol in benzizotiazol kinaze
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
CN101006988A (zh) * 2005-09-26 2007-08-01 刘凤鸣 葛根素的缓释制剂
EP1965762A1 (en) * 2005-12-23 2008-09-10 Alcon, Inc. Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
US20070149593A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
BRPI0721885A2 (pt) * 2007-07-20 2014-02-25 Alcon Inc Formulação farmacêutica para distribuição de compostos inibidores de receptores de tirosina quinase (rtki) para os olhos

Also Published As

Publication number Publication date
EP2403335B1 (en) 2014-08-20
US20100227905A1 (en) 2010-09-09
CA2753690A1 (en) 2010-09-10
MX2011008731A (es) 2011-09-29
ES2508290T3 (es) 2014-10-16
WO2010101992A1 (en) 2010-09-10
JP5583146B2 (ja) 2014-09-03
JP2012519694A (ja) 2012-08-30
EP2403335A1 (en) 2012-01-11
US20130137741A1 (en) 2013-05-30
AU2010221369B2 (en) 2014-03-13
CN102340991A (zh) 2012-02-01
EP2403335A4 (en) 2012-08-29
BRPI1012302A2 (pt) 2015-09-22
ZA201105505B (en) 2013-10-30
AU2010221369A1 (en) 2011-08-25
CN102340991B (zh) 2014-02-26
KR20110130454A (ko) 2011-12-05

Similar Documents

Publication Publication Date Title
KR20160135372A (ko) 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물
AU2010221438C1 (en) Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
ES2369554T3 (es) Carboxi-amido-triazoles para el tratamiento local de enfermedades oculares.
KR102882058B1 (ko) 티몰롤을 포함하는 약제학적 조성물
US20110117189A1 (en) Ophthalmic compositions for treating pathologies of the posterior segment of the eye
JP6677827B2 (ja) 眼科用医薬組成物
US20090118262A1 (en) Non-Aqueous Water-Miscible Materials as Vehicles for Drug Delivery
JP2018520093A (ja) 注射可能なデポー製剤
KR20100051811A (ko) 눈에 수용체 티로신 키나제 저해(ｒｔｋｉ) 화합물을 전달하기 위한 약제학적 제제
JP2009528390A (ja) 薬用ラトランキュリン製剤
JP2023099169A (ja) 多標的阻害剤の医薬
WO2025078308A1 (en) Gel formulation for topical ocular use
JP2024512028A (ja) Ｎ－オキソピリジン化合物の発生を抑制する眼疾患の予防または治療用点眼組成物
BR102020000561A2 (pt) Implante polimérico biodegradável revestido por nanofibras poliméricas para administração intraocular de fármacos, processo e uso
TW202038928A (zh) 多目標抑製劑的懸浮液組合物

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20161117

Application number text: 1020117023001

Filing date: 20110930

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20161216

Comment text: Request for Examination of Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20170314

PC1904 Unpaid initial registration fee